Patents by Inventor Georg Schramm
Georg Schramm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9717691Abstract: The present invention relates to a medicament in the form of daily units, which contain an active ingredient combination consisting of a hormone combination with contraceptive action consisting of at least one oestrogen selected from the group consisting of estradiol and ethinyl estradiol and at least one gestagen selected from the group consisting of chlormadinone acetate, 3-?-OH-chlormadinone acetate, 3-?-OH-chlormadinone acetate, 3-?-acetoxy-chlormadinone acetate and 3-?-acetoxy-chlormadinone acetate, and at least one insulin sensitiser and which are combined to provide a dosage form with daily units which only contain an insulin sensitiser as the sole active ingredient, and to the use of this dosage form for preventing or treating pathological disorders caused by polycystic ovary syndrome (PCOS) and for simultaneous contraception.Type: GrantFiled: June 3, 2010Date of Patent: August 1, 2017Assignee: RICHTER GEDEON NYRT.Inventor: Georg Schramm
-
Patent number: 9278072Abstract: The present invention relates to a hormonal contraceptive including 21 to 25 hormone-containing daily units, which contain a combination of ethinyloestradiol in an amount of ?25 ?g and chlormadinone acetate in an amount of ?5 mg, and optionally 7 to 3 hormone-free daily units for oral administration to women.Type: GrantFiled: December 10, 2004Date of Patent: March 8, 2016Assignee: Richter Gedeon Nyrt.Inventors: Janine Klose, Johannes Bartholomäus, Klaus-Michael Wilsmann, Georg Schramm
-
Patent number: 9107840Abstract: The present invention relates to a hormonal contraceptive including at least 120 hormone-containing daily units, which contain 5 to 50 ?g of ethinyloestradiol and 1 to 5 mg of chlormadinone acetate, and optionally 7 to 3 hormone-free daily units for uninterrupted oral administration to women.Type: GrantFiled: December 10, 2004Date of Patent: August 18, 2015Assignee: Richter Gedeon Nyrt.Inventors: Georg Schramm, Rainer Henske
-
Publication number: 20140249117Abstract: The present invention relates to a medicament, the active ingredient combination of which consists of a retinoid selected from the group consisting of acitretin [9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid], etretinate [ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate], isotretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid] and tretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid] and of a hormone combination with contraceptive action of an oestrogen component and a gestagen component, and to a dosage form consisting of at least 28 daily units, of which the final 7-3 daily units contain only the retinoid as active ingredient and the other daily units also contain the hormone-containing active ingredient combination, and to the use thereof for treating acne, seborrhoea or psoriasis.Type: ApplicationFiled: May 12, 2014Publication date: September 4, 2014Applicant: RICHTER GEDEON NYRT.Inventors: Georg SCHRAMM, Karl-Heinz OEDEKOVEN
-
Patent number: 8580771Abstract: A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women.Type: GrantFiled: October 6, 2005Date of Patent: November 12, 2013Assignee: Richter Gedeon Nyrt.Inventors: Georg Schramm, Eric-Paul Paques
-
Patent number: 8465763Abstract: The present invention relates to the use of 3?-hydroxychlormadinone acetate (17?-acetoxychloropregna-4,6-dien-3?-ol-20-one) and/or 3?-hydroxychlormadinone acetate (17?-acetoxychloropregna-4,6-dien-3?-ol-20-one) for producing a medicament for treating skin, preferably human skin by means of topical application, and to a pharmaceutical or cosmetic composition containing 3?-hydroxychlormadinone acetate and/or 3?-hydroxychlormadinone acetate.Type: GrantFiled: June 12, 2009Date of Patent: June 18, 2013Assignee: Richter Gedeon Nyrt.Inventors: Georg Schramm, Christa Kneip
-
Patent number: 8361995Abstract: The present invention relates to the use of at least one gestagen selected from the group consisting of chlormadinone acetate, 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxy-chlormadinone acetate) and 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxy-chlormadinone acetate) as gestagen component and optionally at least one oestrogen selected from the group consisting of ethinyl oestradiol, oestrone, oestriol as oestrogen component and oestradiol to produce a medicament for the treatment and/or prevention of melasma and optionally for simultaneous hormonal contraception or optionally for simultaneous hormone replacement for women.Type: GrantFiled: September 3, 2009Date of Patent: January 29, 2013Assignee: Richter Gedeon Nyrt.Inventor: Georg Schramm
-
Publication number: 20120053160Abstract: A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain at most 200 ?g of folic acid and the daily units B contain >200 ?g up to the maximum permissible amount of folic acid for women.Type: ApplicationFiled: November 7, 2011Publication date: March 1, 2012Applicant: Gruenenthal GmnHInventors: Georg SCHRAMM, Eric-Paul PAQUES
-
Patent number: 8119620Abstract: A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain at most 200 ?g of folic acid and the daily units B contain >200 ?g up to the maximum permissible amount of folic acid for women.Type: GrantFiled: May 9, 2008Date of Patent: February 21, 2012Assignee: Gruenenthal GmbHInventors: Georg Schramm, Eric-Paul Paques
-
Patent number: 8097604Abstract: The present invention relates to a medicament which contains as the active ingredient combination at least one gestagen with a contraceptive action as the sole hormone component and at least one insulin sensitizer, which medicament is in particular suitable for preventing or treating pathological disorders which are caused by polycystic ovary syndrome (PCOS).Type: GrantFiled: December 1, 2008Date of Patent: January 17, 2012Assignee: Gruenenthal GmbHInventor: Georg Schramm
-
Publication number: 20110172197Abstract: A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women.Type: ApplicationFiled: March 23, 2011Publication date: July 14, 2011Applicant: Grunenthal GmbHInventors: Georg SCHRAMM, Eric-Paul PAQUES
-
Publication number: 20110015161Abstract: The present invention relates to a medicament in the form of daily units, which contain an active ingredient combination consisting of a hormone combination with contraceptive action consisting of at least one oestrogen selected from the group consisting of estradiol and ethinyl estradiol and at least one gestagen selected from the group consisting of chlormadinone acetate, 3-?-OH-chlormadinone acetate, 3-?-OH-chlormadinone acetate, 3-?-acetoxy-chlormadinone acetate and 3-?-acetoxy-chlormadinone acetate, and at least one insulin sensitiser and which are combined to provide a dosage form with daily units which only contain an insulin sensitiser as the sole active ingredient, and to the use of this dosage form for preventing or treating pathological disorders caused by polycystic ovary syndrome (PCOS) and for simultaneous contraception.Type: ApplicationFiled: June 3, 2010Publication date: January 20, 2011Applicant: GRUENENTHAL GMBHInventor: GEORG SCHRAMM
-
Publication number: 20100063014Abstract: The present invention relates to the use of at least one gestagen selected from the group consisting of chlormadinone acetate, 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxy-chlormadinone acetate) and 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxy-chlormadinone acetate) as gestagen component and optionally at least one oestrogen selected from the group consisting of ethinyl oestradiol, oestrone, oestriol as oestrogen component and oestradiol to produce a medicament for the treatment and/or prevention of melasma and optionally for simultaneous hormonal contraception or optionally for simultaneous hormone replacement for women.Type: ApplicationFiled: September 3, 2009Publication date: March 11, 2010Applicant: GRÜNENTHAL GMBHInventor: GEORG SCHRAMM
-
Publication number: 20090318395Abstract: The present invention relates to the use of 3?-hydroxychlormadinone acetate (17?-acetoxychloropregna-4,6-dien-3?-ol-20-one) and/or 3?-hydroxychlormadinone acetate (17?-acetoxychloropregna-4,6-dien-3?-ol-20-one) for producing a medicament for treating skin, preferably human skin by means of topical application, and to a pharmaceutical or cosmetic composition containing 3?-hydroxy-chlormadinone acetate and/or 3?-hydroxychlormadinone acetate.Type: ApplicationFiled: June 12, 2009Publication date: December 24, 2009Applicant: GRUNENTHAL GMBHInventors: GEORG SCHRAMM, CHRISTA KNEIP
-
Publication number: 20090312296Abstract: The present invention relates to a medicament, the active ingredient combination of which consists of a retinoid selected from the group consisting of acitretin [9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid], etretinate [ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate], isotretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid] and tretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid] and of a hormone combination with contraceptive action of an oestrogen component and a gestagen component, and to a dosage form consisting of at least 28 daily units, of which the final 7-3 daily units contain only the retinoid as active ingredient and the other daily units also contain the hormone-containing active ingredient combination, and to the use thereof for treating acne, seborrhoea or psoriasis.Type: ApplicationFiled: June 12, 2009Publication date: December 17, 2009Applicant: GRUNENTHAL GMBHInventors: GEORG SCHRAMM, KARL-HEINZ OEDEKOVEN
-
Publication number: 20090118245Abstract: The present invention relates to a medicament which contains as the active ingredient combination at least one gestagen with a contraceptive action as the sole hormone component and at least one insulin sensitiser, which medicament is in particular suitable for preventing or treating pathological disorders which are caused by polycystic ovary syndrome (PCOS).Type: ApplicationFiled: December 1, 2008Publication date: May 7, 2009Applicant: GRUNENTHAL GMBHInventor: GEORG SCHRAMM
-
Publication number: 20090023694Abstract: The present invention relates to an administration form for hormonal contraception consisting of a particular number of hormone-containing daily units, comprising a hormone combination consisting of at least one oestrogen selected from the group comprising ethinyl oestradiol (I) and oestradiol (II) as the oestrogen component, and at least one metabolite of chlormadinone acetate selected from the group comprising 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxy-chlormadinone acetate), 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-2-one (3?-hydroxy-chlormadinone acetate), optionally mixed with chlormadinone acetate and/or 3?-hydroxy-17?-acetoxy-5?-pregnan-20-one and/or 3?-hydroxy-17?-acetoxy-5?-pregnan-20-one as the gestagen component for the uninterrupted, daily, oral administration of the hormone-containing daily units, optionally in combination with 7 to 3 hormone-free daily units.Type: ApplicationFiled: July 8, 2008Publication date: January 22, 2009Applicant: GRUNENTHAL GMBHInventors: Georg Schramm, Christa Kneip, Johannes Schneider
-
Publication number: 20080312200Abstract: The present invention relates to the use of a hormone combination of ethinyl oestradiol or oestradiol as oestrogen component and at least one metabolite of chlormadinone acetate selected from the group consisting of 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxychlormadinone acetate), 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxychlormadinone acetate), 3?-hydroxy-17?-acetoxy-5?-pregnan-20-one and 3?-hydroxy-17?-acetoxy-5?-pregnan-20-one, optionally mixed with chlormadinone acetate as gestagen component for producing a medicament at least for alleviating menstrual cycle-dependent mood swings and optionally for hormonal contraception in women.Type: ApplicationFiled: July 8, 2008Publication date: December 18, 2008Applicant: Grunenthal GmbHInventors: Georg Schramm, Christa Kneip
-
Publication number: 20080261934Abstract: A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain at most 200 ?g of folic acid and the daily units B contain >200 ?g up to the maximum permissible amount of folic acid for women.Type: ApplicationFiled: May 9, 2008Publication date: October 23, 2008Applicant: Gruenenthal GmbHInventors: Georg SCHRAMM, Eric-Paul Paques
-
Publication number: 20060089338Abstract: A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women.Type: ApplicationFiled: October 6, 2005Publication date: April 27, 2006Inventors: Georg Schramm, Eric-Paul Paques